Company: SMNR
Filing Date: 2025-07-02
Form Type: CORRESP
Source: 0001193125-25-154943
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: CORRESP
Chunk 2
---
, costs or expenses. Please also file a form of the Transition Services Agreement or explain what aspects of the arrangement have not been determined to date.                                |

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 337 of Amendment No. 3 and filed the form of Transition Services Agreement as Exhibit 10.26 in response to the Staff’s comment. Semnur Pharmaceuticals, Inc. Notes to Financial Statements Note 7. Commitments and Contingencies Subsidiary Guarantee to Oramed Note, page F-80

Response: The Company acknowledges the Staff’s comment and respectfully refers to the Staff to (i) the definition of “Excluded Subsidiary” in the Form of Tranche B Senior Secured Convertible Note issued by Scilex Holding Company, filed as Exhibit 4.1 to the Form 8-Kfiled with the Commission by Scilex Holding Company on October 8, 2024 (the “ October Form 8-K”) and (ii) Section 22 of the Amended and Restated Security Agreement, dated October 8, 2024, by and among Scilex Holding Company, the Subsidiaries of Scilex Holding Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (the “ Security Agreement”), filed as Exhibit 10.8 to the October Form 8-K.The Company respectfully advises the Staff that pursuant to Section 22 of the Security Agreement, upon completion of the Business Combination, as an “Excluded Subsidiary”, Semnur will no longer be a Guarantor under the Subsidiary Guarantee. * * * 2

U.S. Securities and Exchange Commission July 2, 2025 Please do not hesitate to contact Michael Blankenship of Winston & Strawn LLP at (713) 651-2678with any questions or comments regarding this letter.

| Sincerely, |     |                         |
| By:        |     | /s/ Lei Huang           |
|            |     | Lei Huang               |
|            |     | Chief Executive Officer |

| cc: | Michael Blankenship, Winston & Strawn LLP |

Jeff Hartlin, Paul Hastings LLP Elizabeth Razzano, Paul Hastings LLP Jaisim Shah, Chief Executive Officer and President, Semnur Pharmaceuticals, Inc. 3